Veterinary Drug terms — page 20 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Terbutaline 5-[2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl]-1,3-benzenediol; Terbutaline; Brican
Terfenadine alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; terfenadine; 50679-08-8; Seldane; Ternadin; Triludan; Teldane; Allerplus; Teldanex; Aldaban; Terdin; TerfenadiTerfen; RMI 9918; RMI-9918; Terfenadinum [INN-Latin]; Terfenadina [INN-Spanish]; MDL 9918; C32H41NO2; HSDB 6508; MDL-9918; EINECS 256-710-8; BRN 5857899; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; CHEMBL17157; MLS000028499; CHEBI:9453; Cyater; GUGOEEXESWIERI-UHFFFAOYSA-N; alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; 1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; 1-Piperidinebutanol, .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-; 1-Piperidinebutanol, alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-; Seldane-D; NCGC00016064-04; NCGC00016064-06; Terfenadinum; SMR000058260; Terfex; DSSTox_CID_3642; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; DSSTox_RID_77124; DSSTox_GSID_23642; 1-(4-tert-butylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol; 1-(4-(tert-Butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)-piperidin-1-yl)butan-1-ol; 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol; alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; Seldane (TN); SR-01000000104; Terfenadine [USAN:BAN:INN:JAN]; teraenadine; UNII-7BA5G9Y06Q; Terfenadin; Terfenadine (JAN/USAN/INN); Terfenadine,(S); 1-(4-tert-Butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol; (-)-Terfenadine; Prestwick_460; CAS-50679-08-8; MFCD00079622; Terfenadine [USAN:USP:INN:BAN:JAN]; Opera_ID_334; Prestwick0_000138; Prestwick1_000138; Prestwick2_000138; Prestwick3_000138; (.+/-.)-Terfenadine; T 9652; SCHEMBL5152; alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; Lopac0_001213; Oprea1_343139; BSPBio_000216; MLS001148415; DivK1c_001011; SPBio_002155; 7BA5G9Y06Q; BPBio1_000238; GTPL2608; DTXSID2023642; HMS503K03; KBio1_001011; NINDS_001011; HMS1568K18; HMS2089I14; HMS2093I11; HMS2095K18; HMS2231N07; HMS3263D08; HMS3373J07; HMS3712K18; Pharmakon1600-01503708; HY-B1193; Tox21_110295; Tox21_110296; Tox21_501213; AC-928; BDBM50017376; BG0333; NSC665802; NSC758627; s4353; AKOS015962091; Tox21_110295_1; API0024492; CCG-205287; CS-4800; DB00342; LP01213; MCULE-8216311776; NSC-665802; NSC-758627; SDCCGSBI-0051180.P004; VA11848; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]-1-piperidyl]butan-1-ol; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol; ACM50679088; IDI1_001011; NCGC00016064-03; NCGC00016064-05; NCGC00016064-08; NCGC00016064-09; NCGC00016064-12; NCGC00089746-02; NCGC00089746-03; NCGC00089746-04; NCGC00261898-01; AC-15791; CC-34708; NCI60_022784; SBI-0051180.P003; DB-051821; LS-114369; AB00052367; EU-0101213; FT-0630637; ST50307835; SW196677-3; BIM-0051180.0001; C07463; D00521; AB00052367-16; AB00052367_17; AB00052367_18; C-22717; L000888; Q417909; ( inverted exclamation markA)-Terfenadine; MDL-991; ( inverted exclamation markA)-Terfenadine; MDL-9918; SR-01000000104-2; SR-01000000104-4; SR-01000000104-7; BRD-A06352418-001-03-6; BRD-A06352418-001-15-0; Terfenadine, European Pharmacopoeia (EP) Reference Standard; Terfenadine, United States Pharmacopeia (USP) Reference Standard; .alpha.-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; 1-[4-(tert-butyl)phenyl]-4-[4-(hydroxydiphenylmethyl)piperidyl]butan-1-ol; (+/-)1-(4-tert-butylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol; (RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol; .alpha.-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; .alpha.-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; 1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol; 1-(4-tert-Butylphenyl)-4-(4-[hydroxy(diphenyl)methyl]-1-piperidinyl)-1-butanol #; 1-(4-tert-butylphenyl)-4-[4-[hydroxy-di(phenyl)methyl]piperidin-1-yl]butan-1-ol; 1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol(Terfenadine); Terfenadine; Aldaban
Terpinen-4-ol 4-Methyl-1-(1-methylethyl)-3-cyclohexen-1-ol; Terpinen-4-ol; 562-74-3; 4-Carvomenthenol; 4-Terpineol; 1-Terpinen-4-ol; p-Menth-1-en-4-ol; Terpinenol-4; 4-Terpinenol; Terpene-4-ol; 1-Menthene-4-ol; 1-p-Menthen-4-ol; TERPINENE-4-OL; 3-Cyclohexen-1-ol, 4-methyl-1-(1-methylethyl)-; 1-para-Menthen-4-ol; (+-)-p-Menth-1-en-4-ol; 4-Methyl-1-(1-methylethyl)-3-cyclohexen-1-ol; Terpinenolu-4 [Czech]; (+/-)-4-Terpineol; 1-Methyl-4-isopropyl-1-cyclohexen-4-ol; 4-Methyl-1-isopropyl-3-cyclohexen-1-ol; Terpineol-4; Terpinine-4-ol; (+/-)-Terpinen-4-ol; 4-Carvomenthenol (natural); 4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol; NSC 147749; FEMA No. 2248; CCRIS 9067; Terpin-4-en-1-ol; para-Menth-1-en-4-ol; EINECS 209-235-5; EINECS 248-910-9; 1-isopropyl-4-methylcyclohex-3-enol; (+/-)-1-Isopropyl-4-methyl-3-cyclohexen-1-ol; BRN 1906603; 4-methyl-1-propan-2-ylcyclohex-3-en-1-ol; CHEBI:78884; WRYLYDPHFGVWKC-UHFFFAOYSA-N; Terpinen-4-ol, 97%; (1)-1-(Isopropyl)-4-methylcyclohex-3-en-1-ol; L-4-terpineneol; L-4-terpineol; L-terpinen-4-ol; Terpinenolu-4; 4-methyl-1-(methylethyl)cyclohex-3-en-1-ol; Origanol; alpha-terpinen-4-ol; alpha -Terpinen-4-ol; 1-Isopropyl-4-methyl-3-cyclohexen-1-ol, (R)-; 1-isopropyl-4-methyl-cyclohex-3-en-1-ol; DSSTox_CID_24824; DSSTox_RID_80505; DSSTox_GSID_44824; SCHEMBL22344; 4-06-00-00250 (Beilstein Handbook Reference); (-)-p-Menth-1-en-4-ol; CHEMBL507795; DTXSID4044824; CTK3J7764; FEMA 2248; HSDB 8264; KS-00000YHW; (+/-)-p-Menth-1-en-4-ol; Tox21_301785; MFCD00001562; NSC147749; s6118; SBB071495; AKOS015903412; CS-W018032; DB12816; HY-W017316; LS-2615; MCULE-6511194668; NSC-147749; RTR-019770; 4-Carvomenthenol, >=95%, FCC, FG; 1-isopropyl-4-methylcyclohex-3-en-1-ol; NCGC00256250-01; 1-Isopropyl-4-methyl-3-cyclohexen-1-ol; 4-Carvomenthenol, natural, >=95%, FG; AK516333; AS-56462; CAS-562-74-3; SC-46918; ST096089; SY012857; DB-066063; TR-019770; FT-0619472; M0319; (-)-1-Isopropyl-4-methyl-3-cyclohexen-1-ol; C17073; Q416114; (+/-)-1-(isopropyl)-4-methylcyclohex-3-en-1-ol; (-)-4-Hydroxy-4-isopropyl-1-methyl-1-cyclohexene; (+/-)-4-Hydroxy-4-isopropyl-1-methyl-1-cyclohexene; Terpinen 4-ol, primary pharmaceutical reference standard; 3-CYCLOHEXEN-1-OL; 4-METHYL-1-(1-METHYLETHYL)-; Terpinenol-4; 4-06-00-00250 (Beilstein Handbook Reference)
Tert-Butylhydroquinone 2-(1,1-Dimethylethyl)-1,4-benzenediol; tert-Butylhydroquinone; 1948-33-0; TBHQ; 2-tert-Butylhydroquinone; 2-tert-butylbenzene-1,4-diol; T-BUTYLHYDROQUINONE; MTBHQ; t-Butyl hydroquinone; 2-t-Butylhydroquinone; 2-tert-Butyl-1,4-benzenediol; Mono-tert-butylhydroquinone; Sustane; tert-Butyl-1,4-benzenediol; Mono-tertiarybutylhydroquinone; Tenox TBHQ; tertiary-Butylhydroquinone; 1,4-Benzenediol, 2-(1,1-dimethylethyl)-; Hydroquinone, tert-butyl-; Banox 20BA; 2-(1,1-Dimethylethyl)-1,4-benzenediol; 2-tert-Butyl(1,4)hydroquinone; 2-tertiary-butylhydroquinone; 2-(tert-butyl)benzene-1,4-diol; tert-Butylhydrochinone; 2-t-Butyl-1,4-benzenediol; t-BHQ; Hydroquinone, t-butyl-; Tertiary butylhydroquinone; Eastman MTBHQ; NSC 4972; monotertiary butyl hydroquinone; CCRIS 1447; HSDB 838; 1,4-Benzenediol (1,1-dimethylethyl)-; CHEBI:78886; tert-butyl-hydroquinone; NSC4972; UNII-C12674942B; Butylhydroquinone, tert-; EINECS 217-752-2; MFCD00002344; BRN 0637923; 2-(1,1-dimethylethyl)benzene-1,4-diol; tert-Butylhydroquinone, 97%; AI3-61039; BGNXCDMCOKJUMV-UHFFFAOYSA-N; NSC-4972; NCGC00013051-05; E319; DSSTox_CID_220; C12674942B; DSSTox_RID_75441; DSSTox_GSID_20220; EYK; CAS-1948-33-0; Butylhydroquinone, t-; Tenox 20; 1-t-Butyl-1,4-dihydroxybenzene; Sustane TBHQ; Tenox TBHO; Tenox TBHQTBHQ; t-butyl-hydroquinone; tert-Butylhydroquinon; tert-butyl hydroquinone; 2-t-butyl hydroquinone; PubChem14585; ACMC-1BWLA; tert.-butyl hydroquinone; 2-tert-butyl-hydroquinone; EC 217-752-2; NCIStruc1_000241; NCIStruc2_000017; SCHEMBL26745; KSC174K6N; MLS002222348; Mono-Tertiarybuytl Hydroquinone; CHEMBL242080; DTXSID6020220; CTK0H4566; KS-00000WWQ; NCI4972; WLN: QR DQ BX1&1&1; KUC109743N; ZINC388085; 1,4-dihydroxy-2-tert-butylbenzene; 2-tert-butyl-1,4-dihydroxybenzene; Tox21_110006; Tox21_110007; Tox21_202309; Tox21_300081; 2-tert-Butyl-1,4-dihydroxybenzene.; ANW-23659; BDBM50065387; CCG-37948; LS-971; NCGC00013051; s4990; STK372011; AKOS003627061; CS-5774; DB07726; MCULE-3339750019; NE10178; RTR-009060; TRA0073543; NCGC00013051-01; NCGC00013051-02; NCGC00013051-03; NCGC00013051-04; NCGC00013051-06; NCGC00013051-07; NCGC00013051-08; NCGC00013051-09; NCGC00013051-10; NCGC00090788-01; NCGC00090788-02; NCGC00090788-03; NCGC00090788-04; NCGC00254178-01; NCGC00259858-01; AC-10579; AK-49529; NCI60_004196; SMR001253806; KSC-241-078-1; tert-Butylhydroquinone, analytical standard; DB-019879; HY-100489; TR-009060; B0833; FT-0652102; ST24027670; ST50824898; 2-(1,1-Dimethylethyl)-1,4-benzenediol, 9CI; Q662443; W-107698; BRD-K36452089-001-01-8; BRD-K36452089-001-02-6; F0001-0696; Z1945707490; 1,4-Benzenediol, 2-(1,1-dimethylethyl)-; 4-06-00-06013 (Beilstein Handbook Reference)
Tert-butyl hydroperoxide 1,1-Dimethylethyl hydroperoxide; tert-Butyl hydroperoxide; 4-01-00-01616 (Beilstein Handbook Reference)
Testosterone (17beta)-17-Hydroxyandrost-4-en-3-one; testosterone; 58-22-0; Testosteron; Androderm; Testoderm; Testim; Mertestate; Virosterone; Androlin; Oreton; AndroGel; Synandrol F; Testosteroid; Andronaq; Andropatch; Andrusol; Homosteron; Homosterone; Malerone; Orquisteron; Primotest; Primoteston; Sustanone; Testandrone; Testobase; Testogel; Testopropon; Testoviron; Testrone; trans-Testosterone; Relibra; Teslen; Testryl; Testiculosterone; Cristerona T; Cristerone T; Testoviron T; Testostosterone; Testoviron Schering; Geno-cristaux gremy; LibiGel; 17beta-Hydroxyandrost-4-en-3-one; Neo-Hombreol F; Oreton-F; Sustanon; Testoject-50; Testosterona; Testosteronum; Striant; Andro 100; Testex; Testosterone hydrate; Percutacrine androgenique; Neo-testis; Sustason 250; Testoderm Tts; beta testosterone; Malestrone (amps); Intrinsa; Perandren; Virormone; Malogen, aquaspension injection; Testosteronum [INN-Latin]; Testosterona [INN-Spanish]; Neotestis; Androst-4-en-17beta-ol-3-one; Testolin; CDB 111C; Testosterone and its esters; 17beta-Hydroxy-4-androsten-3-one; 7-beta-Hydroxyandrost-4-en-3-one; COL 1621; delta4-Androsten-17beta-ol-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 4-Androsten-17beta-ol-3-one; CP 601B; Testro AQ; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; delta(sup 4)-Androsten-17(beta)-ol-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; UNII-3XMK78S47O; CCRIS 574; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; AA 2500; Androst-4-en-3-one, 17beta-hydroxy-; Androst-4-en-3-one, 17-hydroxy-, (17beta)-; Androst-4-en-3-one, 17-beta-hydroxy-; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; CHEBI:17347; (17beta)-17-Hydroxyandrost-4-en-3-one; HSDB 3398; NSC 9700; EINECS 200-370-5; 3XMK78S47O; Testosterone [Androgenic steroids, anabolic]; Androst-4-en-3-one, 17-hydroxy-, (17b)-; MUMGGOZAMZWBJJ-DYKIIFRCSA-N; Androst-4-en-3-one, 17-hydroxy-, (17-beta)-; Testopel Pellets; Halotensin; Fortesta; Nasobol; Natesto; Vogelxo; (+)-testosterone; Axiron; Tefina; CompleoTRT; Testosterone [INN:BAN]; (8alpha,10alpha,13alpha,14beta,17alpha)-17-hydroxyandrost-4-en-3-one; Androderm (TN); Androgel 1%; 17.beta.-Testosterone; Androgel (TN); SMR000058344; Striant (TN); Bio-T-Gel; Testim (TN); Androgel 1.62%; Androst-4-en-3-one, 17-hydroxy-, (17.beta.)-; Testosterone (JAN/USP); Androst-4-en-3-on-17B-ol; CHEMBL386630; component of Duogen (Salt/Mix); component of Tostrex (Salt/Mix); component of Di-Met (Salt/Mix); component of Intrinsa (Salt/Mix); 4-Androsten-17.beta.-ol-3-one; 4-Androsten-3-one-17.beta.-ol; Tlando; component of Di-Genik (Salt/Mix); 4-Androsten-3-one, 17b-hydroxy-; NSC-9700; Testosterone [USP:INN:BAN]; component of Mal-O-Fem (Salt/Mix); 4-androstene-17beta-ol-3-one; Testosterone ciii; 17b-hydroxy-4-androsten-3-one; delta4-androsten-17b-ol-3-one; LPCN 1021; Testosterone, 1; 3kdm; 17-.beta.-Hydroxyandrost-4-en-3-one; NCGC00091018-01; CPD000058344; Axiron (TN); CMC_13449; mpp10; 17.beta.-Hydroxy-.DELTA.4-androsten-3-one; 17-Hydroxyandrost-4-en-3-one, (17.beta.)-; Testosterone, >=98%; DSSTox_CID_2371; Epitope ID:135865; EC 200-370-5; Testosterone EP Impurity C; SCHEMBL8452; DSSTox_RID_76563; DSSTox_GSID_22371; MLS000563091; MLS001032098; MLS001306401; MLS001424262; MLS002174283; BIDD:ER0555; BDBM8885; GTPL2858; DTXSID8022371; 17beta-hydroxy-4-androsten-3one; Testosterone, cell culture tested; 1i37; HMS2052N11; HMS2272B03; HMS2272P03; (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Tox21_200689; HY-15554A; LMST02020002; RB3046; AKOS015894897; ZINC118912393; CCG-101189; CS-1415; DB00624; MCULE-1294118086; NC00439; CAS-58-22-0; Testosterone 1.0 mg/ml in Acetonitrile; Testosterone 100 microg/mL in Methanol; (17?)-17-Hydroxyandrost-4-en-3-one; NCGC00258243-01; AC-14899; SC-15109; SMR001261453; Testosterone, purum, >=99.0% (HPLC); LS-148813; Testosterone 100 microg/mL in Acetonitrile; BIM-0061761.0001; C00535; D00075; S00309; W-5033; AB00973630-03; Testosterone, VETRANAL(TM), analytical standard; 003T654; Androst-4-en-3-one, 17-hydroxy, (17.beta.)-; C-18145; Q-101251; Q1318776; B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E; Testosterone, European Pharmacopoeia (EP) Reference Standard; Testosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, drug standard; Testosterone; 4-Androsten-17?-ol-3-one; 17?-Hydroxy-4-androsten-3-one; Testosterone for impurity D identification, European Pharmacopoeia (EP) Reference Standard; Testosterone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0; {2,7}.0; {11,15}]heptadec-6-en-5-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; 17?-hydroxyandrost-4-en-3-one; epitestosterone; 17-epi-Testosterone; 17?-cis-Testosterone; 4-Androstene-17?-ol-3-one; Isotestosterone; Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; Testosterone; Androlin
Testosterone propionate (17beta)-17-(1-Oxopropoxy)androst-4-en-3-one; Testosterone propionate; Agovirin
Tetrac [4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]acetic acid; Tetraiodothyroacetic acid; Acide 3,5,3',5'-tetraiodothyroacetique [French]
Tetracycline (4S,4aS,5aS,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; Abramycin; Tetraverine; Bristaciclina; Panmycin; Robitet; Lemtrex (base); Sanclomycine; Democracin; Bristaciclin .alpha.; Liquamycin, veterinary; Polycycline, antibiotic; Agromicina; Ambramicina; Ambramycin; Biocycline; Cefracycline; Criseociclina; Cyclomycin; Hostacyclin; Lexacycline; Mericycline; Neocycline; Omegamycin; Orlycycline; Polycycline; Purocyclina; Roviciclina; Tetradecin; Tsiklomitsin; Vetacyclinum; Ciclibion; Copharlan; Tetrabon; Tetracyn; Tetrafil; Veracin; Tetracycline I; Deschlorobiomycin; SK-Tetracycline; Tetracycline II; Tetra-Co; Piracaps (base); Centet (base); Achromycin; Steclin; Abricycline; Enterocycline; Limecycline; Medocycline; Micycline; Resteclin; 4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; Amycin; Cytome; Vetquamycin-324 (free base); Bio-tetra; (-)-Tetracycline; Cefracycline suspension; T-125; Tetracycline (internal use); SR-01000311198; Acromicina; Dispatetrin; Tetracyclinbase; Tetraseptine; Ibicyn; Tetra-Proter; NSC108579; NSC-108579; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide; Talsutin (Salt/Mix); Dumocyclin (Salt/Mix); component of Tetrastatin; Mysteclin-F (Salt/Mix); Bristacycline (Salt/Mix); MLS001183730; SCHEMBL2614976; SCHEMBL4092221; CHEMBL1315061; CHEMBL1970834; SCHEMBL16245310; CTK6H9492; CTK8G3384; Achromycin, naphthacene derivative; OFVLGDICTFRJMM-UHFFFAOYSA-N; BDBM136690; HMS2232B22; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-; BBL022898; STK177206; AKOS000715021; AKOS022060566; API0004693; MCULE-9174708419; US8865686, Table 1, Compound 1; NCGC00018244-02; NCGC00181125-01; NCGC00188941-01; NCI60_000202; SMR000677914; H3043; SR-01000311198-1; SR-01000311198-2; WLN: L E6 C666 BV FV CU GUTTT&J DQ EQ GVZ HQ IN1&1 MQ M1 RQ; (4S,4aS,5aS,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; 2-[amino(hydroxy)methylidene]-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2h,4h,5h)-trione; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo, (4S,4aS,5aS,6S,12aS)-; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-; 2-Naphthacenecarboxamide,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, [4S-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-; 4-(Dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide, [4S-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-; 7005-26-7; Tetracycline; T-125
Tetracyclines Chlortetracycline; Clomocycline; Demeclocycline; Doxycycline; Eravacycline; Lymecycline; Metacycline; Minocycline; Omadacycline; Oxytetracycline; Penimepicycline; Rolitetracycline; Tetracycline
Tetrahydropyran Tetrahydro-2H-pyran; TETRAHYDROPYRAN; Tetrahydro-2H-pyran; 142-68-7; Oxacyclohexane; 2H-Pyran, tetrahydro-; Pentamethylene oxide; Tetrahydropyrane; UNII-V06I3ILG6B; 2H-tetrahydropyran; EINECS 205-552-8; V06I3ILG6B; DHXVGJBLRPWPCS-UHFFFAOYSA-N; Tetrahydropyran, 99%; PYE; Oxane (VAN); tetrahydro-pyran; HSDB 126; 1,1-dioxane; NSC 65448; Tetrahydro-4H-pyran; PubChem9509; AI3-16499; ACMC-1BP0T; KSC178S7T; DTXSID3059719; CHEBI:46941; CTK0H8979; KS-00000WFO; Tetrahydropyran, anhydrous, 99%; NSC65448; ZINC1692451; 7319AF; MFCD00006585; NSC-65448; AKOS009031627; DB02412; RTR-005458; TRA0023566; DB-042642; TR-005458; FT-0631828; ST24050131; 7844-EP2270010A1; 7844-EP2305661A1; 7844-EP2305668A1; 7844-EP2305684A1; 7844-EP2311840A1; 7844-EP2316905A1; 9109-EP2269651A2; 9109-EP2270010A1; 9109-EP2272517A1; 9109-EP2272837A1; 9109-EP2272839A1; 9109-EP2272840A1; 9109-EP2272846A1; 9109-EP2272848A1; 9109-EP2275411A2; 9109-EP2277858A1; 9109-EP2279751A2; 9109-EP2281818A1; 9109-EP2284148A1; 9109-EP2284149A1; 9109-EP2287167A1; 9109-EP2289892A1; 9109-EP2289893A1; 9109-EP2289965A1; 9109-EP2292593A2; 9109-EP2292611A1; 9109-EP2298756A1; 9109-EP2298767A1; 9109-EP2298828A1; 9109-EP2301930A1; 9109-EP2305250A1; 9109-EP2305651A1; 9109-EP2305688A1; 9109-EP2308510A1; 9109-EP2308562A2; 9109-EP2308839A1; 9109-EP2308840A1; 9109-EP2308854A1; 9109-EP2308857A1; 9109-EP2308872A1; 9109-EP2314575A1; 9109-EP2314587A1; 9109-EP2316829A1; 9109-EP2371811A2; 9109-EP2380568A1; 17933-EP2280009A1; 17933-EP2314586A1; 26066-EP2272509A1; 26066-EP2295426A1; 26066-EP2295427A1; 26066-EP2308851A1; 26066-EP2314558A1; 142210-EP2270010A1; 142210-EP2287159A1; 142210-EP2289887A2; 142210-EP2289888A2; 142210-EP2292593A2; A807947; Q412815; J-524857; InChI=1/C5H10O/c1-2-4-6-5-3-1/h1-5H; F0001-0499; Tetrahydropyran; AI3-16499
Tetrodotoxin (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-Amino-1,4,4a,5,9,10-hexahydro-12-(hydroxymethyl)-5,9:7,10a-dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol; Tetrodotoxin; 4-27-00-08206 (Beilstein Handbook Reference)
Thallous chloride Thallium chloride; EINECS 232-241-4; Thallium chloride (TlCl3); EINECS 236-625-2; 13453-32-2
Theobromine theobromine; 83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theosalvose; Theostene; Santheose; Thesodate; 3,7-dimethylpurine-2,6-dione; Thesal; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); FEMA No. 3591; UNII-OBD445WZ5P; NSC 5039; 2,6-Dihydroxy-3,7-dimethyl-purine; MFCD00022830; BRN 0016464; CCRIS 2350; HSDB 7332; 3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; EINECS 201-494-2; CHEMBL1114; OBD445WZ5P; CHEBI:28946; NSC5039; YAPQBXQYLJRXSA-UHFFFAOYSA-N; NSC-5039; Theobromine, 99%; CAS-83-67-0; NCGC00016023-11; DSSTox_CID_6132; 3,7-Dimethyl-1H-purine-2,6(3H,7H)-dione; 3,7-dimethyl-1,3,7-trihydropurine-2,6-dione; DSSTox_RID_78030; DSSTox_GSID_26132; 7-Dimethylxanthine; Theobromine [BAN]; SR-01000000069; Theobromine [INN:BAN:NF]; Xantheose; paraxanthine; Theobromine; Cocoa Theobromine; 37T; Prestwick_1054; Theobromine(20%); 3,7-dimethylxanthin; 3,7-dimethyl xanthine; Spectrum_000053; 3,7-Dimethyl-xanthine; Prestwick0_000874; Prestwick1_000874; Prestwick2_000874; Prestwick3_000874; Spectrum2_000985; Spectrum3_000279; Spectrum4_000403; Spectrum5_001387; Lopac-T-4500; ACMC-209pt0; SCHEMBL3184; Theobromine, >=98.0%; Lopac0_001187; BSPBio_000947; BSPBio_001758; KBioGR_000666; KBioSS_000433; 5-26-13-00553 (Beilstein Handbook Reference); KSC491G3F; MLS000028407; ARONIS24350; DivK1c_000611; SPECTRUM1500649; SPBio_001049; SPBio_002868; BPBio1_001043; ZINC2151; Theobromine, analytical standard; DTXSID9026132; CTK3J1332; HMS501O13; KBio1_000611; KBio2_000433; KBio2_003001; KBio2_005569; KBio3_001258; YAPQBXQYLJRXSA-UHFFFAOYSA-; NINDS_000611; HMS1570P09; HMS1921O13; HMS2092G04; HMS2097P09; HMS3263N15; HMS3714P09; Pharmakon1600-01500649; EBD26471; HY-N0138; Theobromine 0.1 mg/ml in Methanol; Theobromine (3,7-Dimethylxanthine); Theobromine, >=98.0% (HPLC); Tox21_110284; Tox21_300016; Tox21_501187; ANW-37714; BBL034679; BDBM50014260; CCG-40078; NSC757407; PDSP1_001017; PDSP2_001001; s2368; SBB012378; STL419465; AKOS000121558; Tox21_110284_1; 5-26-13-00553 (Beilstein); CS-7972; DB01412; LP01187; LS-1828; LS00156; MCULE-3914097400; NE10843; NSC-757407; SDCCGMLS-0002875.P003; SDCCGSBI-0051154.P004; IDI1_000611; NCGC00016023-01; NCGC00016023-02; NCGC00016023-03; NCGC00016023-04; NCGC00016023-05; NCGC00016023-06; NCGC00016023-07; NCGC00016023-08; NCGC00016023-09; NCGC00016023-10; NCGC00016023-12; NCGC00016023-13; NCGC00016023-14; NCGC00016023-15; NCGC00016023-17; NCGC00016023-18; NCGC00024123-03; NCGC00024123-04; NCGC00024123-05; NCGC00024123-06; NCGC00024123-07; NCGC00024123-08; NCGC00179030-01; NCGC00179030-02; NCGC00253943-01; NCGC00261872-01; WLN: T56 BN DN FNVMVJ B1 F1; AC-11381; AS-13904; BC003475; Q815; SC-06911; SC-90343; SMR000058357; ST069337; SY048379; SBI-0051154.P003; 1H-Purine-2, 3,7-dihydro-3,7-dimethyl-; AB00052141; EU-0101187; FT-0660435; N1573; 7129-EP2269610A2; 7129-EP2277848A1; 7129-EP2277867A2; 7129-EP2280003A2; 7129-EP2284160A1; 7129-EP2289510A1; 7129-EP2295409A1; 7129-EP2298772A1; 7129-EP2301937A1; 7129-EP2305677A1; 7129-EP2305682A1; 7129-EP2308839A1; 7129-EP2308840A1; 7129-EP2308879A1; 7129-EP2311842A2; 7129-EP2314590A1; 7129-EP2314593A1; 7129-EP2316457A1; 7129-EP2316458A1; 7129-EP2316825A1; 7129-EP2316826A1; 7129-EP2316827A1; 7129-EP2316828A1; C07480; T 4500; 59621-EP2308852A1; AB00052141_12; Q206844; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione #; Q-100848; SR-01000000069-2; SR-01000000069-4; SR-01000000069-7; SR-01000000069-8; SR-01000000069-9; 3,7-DIMETHYL-3,7-DIHYDRO-PURINE-2,6-DIONE; BRD-K34888156-001-08-8; CEC63CCA-3B4B-4F4F-92C1-1789DF3C880A; SR-01000000069-10; Z56347209; 1H-purine-2,6-dione,3,7-dihydro-3,7- dimethyl- (9CI); Theobromine, European Pharmacopoeia (EP) Reference Standard; Theobromine, Pharmaceutical Secondary Standard; Certified Reference Material; Theobromine solution, 100 mug/mL in methanol, ampule of 1 mL, certified reference material; InChI=1/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13); 5-26-13-00553 (Beilstein Handbook Reference)
Theophylline 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione; theophylline; 58-55-9; 1,3-Dimethylxanthine; Theophyllin; Elixophyllin; Theolair; Nuelin; Theophylline anhydrous; Respbid; Theocin; Theo-dur; Elixophylline; Pseudotheophylline; Lanophyllin; Theovent; Uniphyl; Slo-phyllin; Accurbron; Armophylline; Bronkodyl; Doraphyllin; Liquophylline; Maphylline; Medaphyllin; Optiphyllin; Parkophyllin; Synophylate; Teofyllamin; Theacitin; Theocontin; Uniphyllin; Xantivent; Aerolate; Elixicon; Solosin; Teolair; Theobid; Theofol; Theograd; Theolix; Elixex; Acet-theocin; Slo-bid; Theophyl-225; Aerolate III; Duraphyl; Euphylong; Sustaire; Xanthium; Austyn; Somophyllin-t; Constant-T; Teofilina; Theochron; Asmax; Quibron T/SR; Theal tablets; Somophyllin-DF; Bronkodyl SR; Theoclair-SR; Theoclear LA; Spophyllin retard; Choledyl SA; Quibron-T; Theoclear 80; Theo-11; Theodur; Theopek; Theospan; Theostat 80; 1,3-dimethyl-7H-purine-2,6-dione; Synophylate-L.A. Cenules; Theophylline, anhydrous; Theo-Dur-Sprinkle; 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione; Aquaphyllin; Theophyline; Theo-24; Theodel; Unifyl; LASMA; Pro-vent; Theona P; LaBID; Euphylline; Elixomin; Teofilina [Polish]; Theolixir; Theophyl; Labophylline; Bronkotabs; Mudrane; Theokin; 1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Hylate; Elixophyllin SR; Theophylline-SR; Somophyllin-CRT; Aerolate SR; Theo-Organidin; Theolair-SR; Theophyl-SR; GS 2591A; Uni-Dur; Theoclear-80; Nuelin SA; Quibron-T/SR; T-Phyl; Bronchodid Duracap; Theoclear-200; Uniphyllin continus; Xanthine, 1,3-dimethyl-; Dimethylxanthine; NSC 2066; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-; X 115; Quadrinal; Theobid Jr.; Theoclear L.A.-130; Theal tabl.; 1,3-dimethyl-1H-purine-2,6(3H,7H)-dione; 1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; UNII-0I55128JYK; CCRIS 4729; HSDB 3399; 2,6-Dihydroxy-1,3-dimethylpurine; Purine-2,6(1H,3H)-dione, 1,3-dimethyl-; EINECS 200-385-7; Aerobin; CHEMBL190; Theophylline [USP]; C7H8N4O2; THEOBID JR; AI3-50216; MLS000069390; Diffumal; Theostat; 1,3-dimethyl-1H-purine-2,6(3H,9H)-dione; CHEBI:28177; ZFXYFBGIUFBOJW-UHFFFAOYSA-N; 0I55128JYK; NSC-2066; 1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurine; 1H-Purine-2,6-dione, 3,9-dihydro-1,3-dimethyl-; NCGC00018117-07; NCGC00018117-17; Uniphylline; Pulmidur; SMR000058537; Teonova; Theonite; Afonilum Retard; DSSTox_CID_1336; 1,3-dimethyl-1,3,7-trihydropurine-2,6-dione; DSSTox_RID_76090; DSSTox_GSID_21336; Quibron T-SR; 75448-53-2; Theophylline, 99+%, anhydrous; Teocen 200; Elixophyllin(e); CAS-58-55-9; Nuelin S.A; Theolair (TN); Elixophyllin (TN); Uniphyl (TN); Quibron-t (TN); Theoconfin Continuous; Theodur G (TN); Glycine Theophyllinate; 1,3-dimethyl-3,9-dihydro-1H-purine-2,6-dione; SR-01000075195; Theo-24 (TN); Telbans; Physpa; Unicontin CR; 4eoh; Aescin-IIA; Theophylline form II; PubChem9695; theophylline solu-tion; component of Primatene; Xanthine,3-dimethyl-; Opera_ID_76; Spectrum_001038; Theophylline (JP17); 2a3a; Theophylline (anhydrous); 3485-82-3; Prestwick0_000820; Prestwick0_000873; Prestwick1_000820; Prestwick1_000873; Prestwick2_000820; Prestwick2_000873; Prestwick3_000820; Prestwick3_000873; Spectrum2_000842; Spectrum3_000672; Spectrum4_000353; Spectrum5_001232; 8-(2-Furyl)theophylline; UPCMLD-DP123; component of Theo-Organidin; EC 200-385-7; SCHEMBL4915; Theophylline Anhydrous,(S); Theophylline Anhydrous, USP; Lopac0_000014; BSPBio_000719; BSPBio_000945; BSPBio_002363; component of Dicurin Procaine; GTPL413; KBioGR_000785; KBioSS_001518; KSC491S8L; MLS002152943; MLS002153487; MLS004491910; MLS006011970; ARONIS25346; BIDD:ER0557; BIDD:GT0151; DivK1c_000203; SPECTRUM1500568; SPBio_000823; SPBio_002640; SPBio_002866; BPBio1_000791; BPBio1_001041; SCHEMBL8312163; component of Tedral (Salt/Mix); DTXSID5021336; UPCMLD-DP123:001; BCBcMAP01_000071; BDBM10847; BDBM82053; component of Quibron (Salt/Mix); CTK3J1985; HMS500K05; KBio1_000203; KBio2_001518; KBio2_004086; KBio2_006654; KBio3_001583; NSC2066; component of Hecadrol (Salt/Mix); NINDS_000203; HMS1921E03; HMS2089A06; HMS2092M05; HMS2233E16; HMS3259O06; HMS3369N14; Pharmakon1600-01500568; Theophylline melting point standard; component of Primatene (Salt/Mix); BCP30664; component of Bronkotabs (Salt/Mix); HY-B0809; Theophylline 1.0 mg/ml in Methanol; Theophylline, >=99.0% (HPLC); Tox21_110827; Tox21_202375; Tox21_300028; BBL023514; CCG-20301; LS-241; MFCD00079619; NSC757346; PDSP1_001018; PDSP1_001234; PDSP2_001002; PDSP2_001218; STK397040; Theophylline (1,3-dimethylxanthine); ZINC18043251; AKOS000120961; AKOS005434016; component of Quibron Plus (Salt/Mix); Tox21_110827_1; component of Quibron-T/SR (Salt/Mix); component of Theo-organdin (Salt/Mix); component of Theolair plus (Salt/Mix); CS-4158; DB00277; MCULE-8236489917; NC00542; NE11194; NSC-757346; Purine-2,3H)-dione, 1,3-dimethyl-; SDCCGMLS-0066620.P001; SDCCGSBI-0050003.P005; component of Theo-Organidin (Salt/Mix); IDI1_000203; KS-000010T0; KS-0000477R; SMP1_000291; component of Slo-phyllin GG (Salt/Mix); NCGC00018117-01; NCGC00018117-02; NCGC00018117-03; NCGC00018117-04; NCGC00018117-05; NCGC00018117-06; NCGC00018117-08; NCGC00018117-09; NCGC00018117-10; NCGC00018117-11; NCGC00018117-12; NCGC00018117-13; NCGC00018117-14; NCGC00018117-15; NCGC00018117-16; NCGC00018117-18; NCGC00018117-19; NCGC00018117-20; NCGC00018117-23; NCGC00022112-03; NCGC00022112-04; NCGC00022112-05; NCGC00022112-07; NCGC00022112-08; NCGC00022112-09; NCGC00022112-10; NCGC00022112-11; NCGC00022112-12; NCGC00254040-01; NCGC00259924-01; WLN: T56 BM DN FNVNVJ F1 H1; AC-20328; component of Dicurin Procaine (Salt/Mix); CPD000058537; NCI60_001736; SAM002554935; SC-05534; SC-95891; SMR003435989; ST024762; Theophylline, anhydrous, >=99%, powder; component of Primatene tablets (Salt/Mix); Purine,6(1H,3H)-dione, 1,3-dimethyl-; SBI-0050003.P004; AB1009249; component of Mudrane GG elixir (Salt/Mix); DB-053224; 1H-Purine-2, 3,7-dihydro-1,3-dimethyl-; AB00052106; FT-0631259; N1442; 6461-EP1441224A2; 6461-EP2272835A1; 6461-EP2272841A1; 6461-EP2272844A1; 6461-EP2280006A1; 6461-EP2281813A1; 6461-EP2281815A1; 6461-EP2286811A1; 6461-EP2295434A2; 6461-EP2298305A1; 6461-EP2301933A1; 6461-EP2301936A1; 6461-EP2301937A1; 6461-EP2305219A1; 6461-EP2305640A2; 6461-EP2308562A2; 6461-EP2311827A1; 6461-EP2314590A1; C07130; D00371; 83377-EP2371823A1; AB00052106-20; AB00052106-22; AB00052106-23; AB00052106_24; AB00052106_25; AB00052106_26; 3,7-dihydro-1,3-dimethyl-1H- purine-2,6-dione; L000595; Q407308; 1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione #; Q-201819; SR-01000075195-1; SR-01000075195-3; SR-01000075195-5; 1,3-Dimethyl-6-hydroxy-1,3-dihydro-2H-purin-2-one; BRD-K97799481-001-02-0; BRD-K97799481-001-12-9; BRD-K97799481-002-03-6; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, mo; F2173-0145; Z271004650; A3133D49-AAB6-49A1-B60B-B5198F327D3F; Theophylline, British Pharmacopoeia (BP) Reference Standard; Theophylline, European Pharmacopoeia (EP) Reference Standard; (8alpha, 9S)-10,11-Dihydro-6'-methoxycinchonan-9-amine trihydrochloride, min. 90%; Theophylline melting point standard, United States Pharmacopeia (USP) Reference Standard; Theophylline solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Theophylline, Pharmaceutical Secondary Standard; Certified Reference Material; 1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurine; 1,3-Dimethylxanthine; 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione; InChI=1/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9; Theo-24; 1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; 1,3-Dimethylxanthine; 1,3-dimethyl-xanthin; Theophylline melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material; Theophylline, certified reference material, United States Pharmacopeia (USP) Reference Standard; Theophylline; X 115
Thiamphenicol 2,2-Dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide; Thiamphenicol; 8065 C.B.
Thioguanine 6-Thioguanine; 6-Thioguanine; thioguanine; 154-42-7; Tioguanine; 2-Amino-6-mercaptopurine; 6-Mercaptoguanine; Tabloid; Tioguanin; Lanvis; 2-Amino-6-purinethiol; 2-Amino 6MP; 2-Aminopurin-6-thiol; 2-Aminopurine-6-thiol; 2-Aminopurine-6(1H)-thione; Wellcome U3B; 6-Mercapto-2-aminopurine; 2-Amino-9H-purine-6-thiol; 6-TG; 2-Amino-6-merkaptopurin; Tioguaninum; Guanine, thio-; Tioguanina; 6H-Purine-6-thione, 2-amino-1,7-dihydro-; 2-Thioguanine; 2-Amino-1,7-dihydro-6H-purine-6-thione; BW 5071; Purine-6-thiol, 2-amino-; Purine-6(1H)-thione, 2-amino-; 2-Amino-6-MP; 2-Amino-1,9-Dihydro-6h-Purine-6-Thione; Tioguaninum [INN-Latin]; NSC-752; TG; 2-Aminopurin-6-thiol [Czech]; THG; Guanine, thio- (VAN); NSC 752; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-6-merkaptopurin [Czech]; X 27; 6-Thioguanine (6-TG); Tioguanina [INN-Spanish]; UNII-WIX31ZPX66; Tioguanine (INN); C5H5N5S; CCRIS 8997; 9H-Purine-6-thiol, 2-amino-; HSDB 2504; EINECS 205-827-2; 2-amino-1,9-dihydropurine-6-thione; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; CHEMBL727; WIX31ZPX66; 2-amino-6,7-dihydro-3H-purine-6-thione; AI3-26078; CHEBI:9555; NSC752; WYWHKKSPHMUBEB-UHFFFAOYSA-N; Tioguanine [INN]; 2-amino-1,7-dihydropurine-6-thione; MFCD00233553; NCGC00094792-01; DSSTox_CID_3652; 2-amino-3,7-dihydropurine-6-thione; DSSTox_RID_77129; DSSTox_GSID_23652; 153981-51-2; 153981-52-3; 154034-61-4; Thioguanine [USAN:BAN]; 6-Tioguanine; CAS-154-42-7; DX4; SMR000857244; Lanvis (TN); Thioguanine Anhydrous; NSC-76504; SR-05000002077; Thioguanine [USAN:USP]; Thioquanine; 7H-Purine-6-thiol, 2-amino-; 6-thioguano-sine; 6-TG/Thioguanine; Tioguanine hemihydrate; PubChem9185; Thioguanine, anhydrous; 6-Thioguanine/6-TG; 1H-Purine-6-thiol, 2-amino- (9CI); Spectrum_000235; ACMC-209dan; Spectrum2_000695; Spectrum3_000577; Spectrum4_000926; Spectrum5_001455; purine antimetabolite: antimetabolite: inhibits nucleic acid replication; 2-Amino-6-mercapto-purin; 6-Thioguanine, >=98%; SCHEMBL3701; SCHEMBL5898; NCIOpen2_004153; BSPBio_001994; C5H7N5S; KBioGR_001452; KBioGR_002476; KBioSS_000715; KBioSS_002483; KSC491M3F; MLS001333131; MLS001333132; MLS006010896; DivK1c_000428; SPECTRUM1500573; 6H-Purine-6-thione, 2-amino-3,7-dihydro- (9CI); SPBio_000849; 154-42-7|6-Thioguanine; 2-amino-6-mercapto-9H-purine; GTPL6845; Thioguanine (TN) (GlaxoSmith); DTXSID6023652; CTK3J1632; HMS501F10; KBio1_000428; KBio2_000715; KBio2_002476; KBio2_003283; KBio2_005044; KBio2_005851; KBio2_007612; KBio3_001494; KBio3_002954; cMAP_000061; NINDS_000428; BCPE000001; HMS1921E09; HMS2092M11; HMS2235F05; Pharmakon1600-01500573; 2-amino-1H-purine-6(9H)-thione; ALBB-023493; BCP27718; ZINC6382803; Tox21_111035; Tox21_113184; Tox21_202401; Tox21_300275; ABP000905; ANW-21501; BDBM50200099; CCG-39890; CT-117; LS-888; NSC757348; s1774; SBB067147; AKOS003389499; AKOS015901298; Tox21_111035_1; 2-Amino-1,7-dihydro-purine-6-thione; 2-Amino-1,9-dihydro-purine-6-thione; AC-8421; API0015888; BCP9000197; CCG-213953; CS-1497; DB00352; FCH1448907; MCULE-5787306636; NSC-757348; PS-5007; VZ33872; WLN: T56 BNM FYM INJ FUS HZ; IDI1_000428; SMP2_000326; NCGC00094792-02; NCGC00094792-03; NCGC00094792-05; NCGC00094792-06; NCGC00188976-01; NCGC00188976-02; NCGC00254082-01; NCGC00259950-01; NCGC00263442-01; 154034-62-5; 4CA-0085; AC-23020; H351; HY-13765; NCI60_041643; SC-01333; SMR004701808; 2-amino-3,7-dihydro-6H-purine-6-thione; SBI-0051533.P003; AB0013003; AB2000285; FT-0083572; FT-0611217; R2215; ST45025337; Y7662; 2-Amino-1,7-dihydro-6H-purine-6-thione #; C07648; D08603; J10163; W-5092; 15151-EP2275420A1; 15151-EP2295055A2; 15151-EP2295416A2; 15151-EP2295426A1; 15151-EP2295427A1; 15151-EP2298748A2; 15151-EP2298764A1; 15151-EP2298765A1; 15151-EP2305642A2; 15151-EP2308833A2; 15151-EP2311453A1; 15151-EP2311808A1; 15151-EP2311825A1; 15151-EP2311829A1; 15151-EP2311840A1; 15151-EP2311842A2; 15151-EP2316832A1; 15151-EP2316833A1; AB00174074_06; AB00918694_06; AB01273926-01; AB01273926-02; AB01273926_03; 120118-EP2270008A1; 120118-EP2272827A1; 120118-EP2292617A1; 120118-EP2298778A1; 154T427; Q385347; SR-05000002077-1; SR-05000002077-5; W-108030; W-205813; Z2768769146; 6-Thioguanine; 6-TG; 2-Amino-6-mercaptopurine; 2-Amino-6-purinethiol; Thioguanine, United States Pharmacopeia (USP) Reference Standard; Thioguanine; 6-TG; 2-Amino-6-mercaptopurine; 2-Amino-6-purinethiol; 6-Thioguanine, Hybri-Max(TM), 50 x, gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; Thioguanine; X 27
Thiopental 5-Ethyldihydro-5-(1-methylbutyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; Thiopental; 5-24-09-00172 (Beilstein Handbook Reference)
Thioridazine 10-[2-(1-Methyl-2-piperidinyl)ethyl]-2-(methylthio)-10H-phenothiazine; Thioridazine; AI3-51923
Thiotepa 1,1',1''-Phosphinothioylidynetrisaziridine; Thiotepa; THIO-TEPA; 52-24-4; Triethylenethiophosphoramide; Thiophosphamide; Tiofosfamid; Tiofosyl; Tespamin; Thioplex; Girostan; Oncotepa; Tespamine; Thiofozil; Tiofozil; Stepa; Oncotiotepa; Thiotef; Tifosyl; Oncothio-tepa; TESPA; Tio-tef; Thio-Tep; TSPA; Thio-tepa S; Ledertepa; Thiotriethylenephosphoramide; TIO TEF; Tri(aziridin-1-yl)phosphine sulfide; Tris(1-aziridinyl)phosphine sulfide; N,N',N''-Triethylenethiophosphoramide; Thiophosphamidum; Triethylene thiophosphoramide; Triaziridinylphosphine sulfide; NSC-6396; Triethylenethiophosphorotriamide; Tris(ethylenimino)thiophosphate; 1,1',1''-phosphorothioyltriaziridine; CBC 806495; Phosphorothioic acid triethylenetriamide; Phosphine sulfide, tris(1-aziridinyl)-; Tri(ethyleneimino)thiophosphoramide; Aziridine, 1,1',1''-phosphinothioylidynetris-; NCI-C01649; NSC 6396; SK 6882; Thiotepum [INN-Latin]; Tiotepa [INN-Spanish]; Tris(aziridinyl)phosphine sulfide; Tri-1-aziridinylphosphine sulfide; Tris(1-aziridinyl)phosphine sulphide; N,N',N''-Triethylenethiophosphamide; UNII-905Z5W3GKH; Phosphoric tri(ethyleneamide); C6H12N3PS; CCRIS 586; N,N',N''-Triethylenethiophosphortriamide; AI3-24916; HSDB 3258; NSC6396; 1,1',1''-Phosphinothioylidynetrisaziridine; N,N',N''-Triethylenephosphorothioic triamide; N,N',N''-Tri-1,2-ethanediylthiophosphoramide; EINECS 200-135-7; Thiophosphoramide, N,N',N''-tri-1,2-ethanediyl-; BRN 0145978; N,N',N''-Tri-1,2-ethanediylphosphorothioic triamide; WR-45312; MLS001333083; MLS003389372; 905Z5W3GKH; CHEBI:9570; Phosphorothioic triamide, N,N',N''-tri-1,2-ethanediyl-; AI 3-24916; FOCVUCIESVLUNU-UHFFFAOYSA-N; Phosphorothioic triamide, N,N',N''-triethylene-; MFCD00145452; tepadina; NCGC00095042-04; NCGC00095042-06; DSSTox_CID_1339; Tris(aziridinyl)-phosphine sulfide (thio-tepa); DSSTox_RID_76093; DSSTox_GSID_21339; Thiotepum; Tiotepa; CAS-52-24-4; SMR000058542; SR-05000001855; Thiotepa [USP:INN:BAN:JAN]; Thiotepa [USAN:INN:BAN:JAN]; N,N',N"-Triethylenethiophosphamide; Tepadina (TN); Thioplex (TN); N,N',N"-Triethylenethiophosphoramide; Rethio (TN); Thiotepa (Thioplex); Spectrum_001689; Thiophosphoramide, N,N',N"-triethylene-; WR 45312; Thiophosphoramide, N,N',N''-triethylene-; Spectrum2_001557; Spectrum3_001594; Spectrum4_000208; Spectrum5_001641; Aziridine, 1,1,1"-phosphinothioylidynetris-; tris(aziridin-1-yl)-thioxo-$l^{5}-phosphane; CHEMBL671; Thioplex (TN) (Immunex); SCHEMBL4760; Phosphorothioic triamide, N,N',N"-triethylene-; Thiotepa (JAN/USP/INN); Triethylenethiop hosphoramide; Thio-TEPA, 98%, solid; BSPBio_003188; KBioGR_000815; KBioSS_002169; 4-20-00-00052 (Beilstein Handbook Reference); KSC917M9N; MLS001333084; MLS002207150; MLS006009972; ARONIS24177; BIDD:GT0127; DivK1c_000817; SPECTRUM1503324; SPBio_001434; GTPL7622; DTXSID0021339; CTK8B7696; HMS502I19; KBio1_000817; KBio2_002169; KBio2_004737; KBio2_007305; KBio3_002688; N,N''-Triethylenethiophosphamide; AOB5373; NINDS_000817; HMS1922A14; HMS2093E05; HMS2232P17; HMS3372D10; N,N''-Triethylenethiophosphoramide; Pharmakon1600-01503324; BCP04110; KS-000010LT; ZINC1530867; Tox21_111399; Tox21_400065; ANW-58232; BDBM50418086; CCG-39776; LS-170; NSC758455; RW2156; s1775; AKOS005267118; CS-3119; DB04572; GC10080; MCULE-5478761622; NSC-758455; RTR-018556; 1,1''-Phosphinothioylidynetrisaziridine; IDI1_000817; Thiophosphoramide,N',N'' -triethylene-; NCGC00095042-01; NCGC00095042-02; NCGC00095042-03; NCGC00095042-05; NCGC00095042-07; NCGC00095042-08; NCGC00095042-09; AS-16885; HY-17574; N,N''-Triethylenephosphorothioic triamide; NCI60_013117; SC-27282; 1,1',1''-Phosphorothioyltris(aziridine); SBI-0051814.P002; tris(1-aziridinyl)-sulfanylidenephosphorane; tris(aziridin-1-yl)-lambda-phosphanethione; AB0006704; AB2000286; Aziridine,1',1''-phosphinothioylidynetris-; N,N''-Tri-1,2-ethanediylthiophosphoramide; Phosphorothioic triamide,N',N''-triethylene; Thiophosphoramide, N,N',N'' -triethylene-; TR-018556; tris(aziridin-1-yl)-lambda5-phosphanethione; Aziridine,1,1',1'-phosphinothioylidynetris-; FT-0082517; FT-0600281; tris(aziridin-1-yl)-$l^{5}-phosphanethione; tris(aziridin-1-yl)-sulfanylidenephosphorane; WLN: T3NTJ APS&- AT3NTJ&- AT3NTJ; Y0223; 1-[Di(1-aziridinyl)phosphorothioyl]aziridine #; C07641; D00583; Phosphorothioic triamide, N,N',N''-triethylene; Thiophosphoramide,N',N''-tri-1,2-ethanediyl-; Z-0841; 24126-EP2272827A1; 24126-EP2272832A1; 24126-EP2275420A1; 24126-EP2280012A2; 24126-EP2292615A1; 24126-EP2295055A2; 24126-EP2295416A2; 24126-EP2295426A1; 24126-EP2295427A1; 24126-EP2298748A2; 24126-EP2298764A1; 24126-EP2298765A1; 24126-EP2298768A1; 24126-EP2298778A1; 24126-EP2301928A1; 24126-EP2305642A2; 24126-EP2308833A2; 24126-EP2311453A1; 24126-EP2314590A1; AB00052346-06; AB00052346_07; N,N',N''-Tri-1,2-et hanediylthiophosphoramide; 145T452; A828998; N,N''-Tri-1,2-ethanediylphosphorothioic triamide; Q416507; Q-201826; SR-05000001855-1; SR-05000001855-5; tris(aziridin-1-yl)-sulfanylidene-$l^{5}-phosphane; AZIRIDINE,1,1',1''-PHOSPHINOTHIOYLIDYNETRIS-; BRD-K09631521-001-05-7; Phosphorothioic triamide,N',N''-tri-1,2-ethanediyl-; Tiofosyl; Tiofosfamid; Triethylenethiophosphoramide; Thioplex; Z2574360269; Thiotepa, United States Pharmacopeia (USP) Reference Standard; Thiotepa; 4-20-00-00052 (Beilstein Handbook Reference)
Thymidine Thymidine; 50-89-5; Deoxythymidine; 2'-Deoxythymidine; Thymidin; Beta-Thymidine; 5-Methyldeoxyuridine; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; dThd; 5-Methyldeoxyurindine; Thymine deoxyriboside; 2'-thymidine; Uridine, 2'-deoxy-5-methyl-; dT; thymine 2'-deoxyriboside; UNII-VC2W18DGKR; Deoxyribothymidine; 2'-deoxy-5-methyluridine; AI3-52267; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748; alpha-tritiated thymidine; Thymine 2-desoxyriboside; EINECS 200-070-4; MFCD00006537; NSC 21548; VC2W18DGKR; Zidovudine Related Compound D; 1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-erythro-pentofuranosyl)-5-methyl-; L-Thymidine; Thymidine, 99+%; [3H]-Thymidine; NCGC00142484-03; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; 157049-39-3; THM; 1-(2-deoxy-beta-D-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(4S,2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-dihydropyri midine-2,4-dione; NSC-21548; deoxyribosylthymine; 4qsv; 3424-98-4; Thymidinedeoxyriboside; PubChem6943; 1w2g; Thymidine, >=99%; Thymidine (8CI,9CI); DSSTox_CID_3661; bmse000244; Epitope ID:138113; EC 200-070-4; 2'-deoxy-5-methyl-Uridine; DSSTox_RID_77133; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-methyluracil; DSSTox_GSID_23661; SCHEMBL19894; KSC170M6B; 2'-dT; CHEMBL52609; GTPL4718; DTXSID5023661; Zidovudine related compound d rs; CTK0H0660; ZINC25672; BIT2044; IQFYYKKMVGJFEH-XLPZGREQSA-N; ZX-AFC000458; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydro-furan-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; ACT03217; HY-N1150; STR05630; Thymidine, >=99.0% (HPLC); ZX-AT021585; Tox21_111560; ANW-31155; CT-111; CT0194; GE6597; HG1139; OR4884; s4803; SBB003204; AKOS015895360; thymine-1 2-deoxy-b-D-Ribofuranoside; AC-1475; AM83949; CS-W019644; DB04485; PB32085; CAS-50-89-5; DEOXYTHYMIDINE; 2'-DEOXYTHYMIDINE; NCGC00142484-01; 1-(2-Deoxy-beta-D-ribofuranosyl)thymine; BR-47328; SC-04918; ST056941; Thymidine, Vetec(TM) reagent grade, 99%; AB0010514; AX8008729; DB-030432; LS-153777; FT-0631214; FT-0674834; FT-0700740; thymine-1 2-deoxy-beta-delta-Ribofuranoside; 1-(2-Deoxy-A-D-ribofuranosyl)-5-methyluracil; 1-(2-Deoxy-beta-ribofuranosyl)-5-methyluracil; C00214; J10255; M-5516; X-3097; Q422464; SR-01000883981; (1-[2-Deoxy-beta-D-ribofuranosyl]-5-methyluracil); 1-(2-Deoxy-.beta.-D-ribofuranosyl)-5-methyluracil; J-700251; SR-01000883981-1; BRD-K28309349-001-02-4; Q27124084; D7E43A69-265B-4DAA-BC8F-193FB357140F; Thymidine, powder, BioReagent, suitable for cell culture; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-(2-Deoxy-b-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione (Thymidine); 1-(2-Deoxy-beta-delta-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione; Zidovudine Related Compound D, United States Pharmacopeia (USP) Reference Standard; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; AI3-52267
Thymine thymine; 5-methyluracil; 65-71-4; 2,4-Dihydroxy-5-methylpyrimidine; Thymin; 5-methylpyrimidine-2,4(1H,3H)-dione; Thymine anhydrate; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-; 5-methyl-2,4(1H,3H)-pyrimidinedione; Thymin (purine base); 5-Methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; 5-methyl-1H-pyrimidine-2,4-dione; CCRIS 5584; UNII-QR26YLT7LT; 5-Methylpyrimidine-2,4-dione; 4-Hydroxy-5-methylpyrimidin-2(1H)-one; CHEBI:17821; AI3-25479; NSC14705; EINECS 200-616-1; MFCD00006026; NSC 14705; QR26YLT7LT; CHEMBL993; 5-Methyl-2,4-dihydroxypyrimidine; RWQNBRDOKXIBIV-UHFFFAOYSA-N; Thymine, 99%; Thy; Thymine-t; 5-Methyl Uracil; (3H)Methylthymidine; 5-methyl-1,3-dihydropyrimidine-2,4-dione; Methyl-3H thymidine; Thymine (8CI); 5-methyl-uracil; 5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE (THYMINE); Thymine,(S); Thymine (VAN); PubChem9313; Thymine, >=99%; Zidovudine EP Impurity C; ACMC-1BI1O; Epitope ID:167476; Thymine (VAN) (8CI); SCHEMBL5235; DSSTox_CID_30914; DSSTox_GSID_52342; 2(1H)-Pyrimidinone, 4-hydroxy-5-methyl- (9CI); 2,4(1H,3H)-Pyrimidinedione, 5-methyl- (9CI); 5-methylpyrimidine-2,4-diol; KSC492E2J; 5-Methyl-2,4-dioxypyrimidine; 2.6-Dioxy-5-methyl-pyrimidin; GTPL4581; DTXSID4052342; SCHEMBL15496760; SCHEMBL16356870; CTK2F2133; CTK3J2224; CTK8G7118; CTK9A1224; WLN: T6N CNJ BQ DQ E1; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-, labeled with tritium; ZINC157062; BCP22973; 2,3H)-Pyrimidinedione, 5-methyl-; Tox21_303929; ANW-35077; BDBM50134397; NSC-14705; s9382; SBB058343; STL280241; STL477641; AKOS000120923; AKOS002337369; AC-7756; AM81332; CS-W011166; DB03462; HY-W010450; MCULE-6356243926; CAS-65-71-4; NCGC00357169-01; 2792-47-4; 5-Methylpyrimidine-2,4(1H,3H); -dione; 69497-78-5; AK-50015; AT-26070; SC-06111; SC-19597; SY014896; Thymine, Vetec(TM) reagent grade, 99%; AB1007210; DB-016098; LS-153797; TC-063833; FT-0602550; ST51016238; KS-00000535; 1605-EP2270010A1; 1605-EP2270015A1; 1605-EP2270505A1; 1605-EP2281563A1; 1605-EP2292088A1; 1605-EP2292593A2; 1605-EP2295414A1; 1605-EP2295441A2; 1605-EP2295503A1; 1605-EP2298783A1; 1605-EP2301536A1; 1605-EP2301538A1; 1605-EP2305808A1; 1605-EP2311455A1; 1605-EP2316452A1; 1605-EP2316459A1; 7412-EP2281563A1; 7412-EP2316459A1; 7412-EP2316974A1; A-8204; C00178; T-3845; Thymine, suitable for cell culture, BioReagent; 006T026; 130594-EP2295441A2; 2,4-Dihydroxy-5-methylpyrimidine; 5-Methyluracil; Q171973; SR-01000945223; SR-01000945223-1; 036B9F1D-9B61-4CED-967C-BF1DA180E5C2; F0001-1753; InChI=1/C5H6N2O2/c1-3-2-6-5(9)7-4(3)8/h2H,1H3,(H2,6,7,8,9; Zidovudine Related Compound C, United States Pharmacopeia (USP) Reference Standard; 3059-73-2; 691841-57-3; Thymine(Zidovudine Related Compound C), Pharmaceutical Secondary Standard; Certified Reference Material; Thymine; USP Zidovudine Related Compound C; 5-Methyluracil; 5-Methylpyrimidine-2,4(1H,3H)-dione; 4-Hydroxy-5-methylyrimidin-2(1H)-one; AI3-25479
Tiaprofenic acid 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; Tiaprofenic acid; 5-18-08-00405 (Beilstein Handbook Reference)
Ticarcillin-clavulanic acid (2R,3Z,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid mixt. with (2S,5R,6R)-6-[[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ticarcillin-clavulanic acid; BRL 28500
Tioconazole 1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; tioconazole; 65899-73-2; Trosyl; Vagistat-1; Vagistat; Trosyd; Gyno-trosyd; Fungibacid; Tioconazolum; Zoniden; Tioconazol [INN-Spanish]; Tioconazolum [INN-Latin]; Tz-3; UK-20349; C16H13Cl3N2OS; UK 20349; EINECS 265-973-8; BRN 0573867; Tioconazol; CHEBI:77898; QXHHHPZILQDDPS-UHFFFAOYSA-N; 1-(2,4-Dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole; (+-)-1-(2,4-Dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; NCGC00167430-01; 1-(2,4-Dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole; DSSTox_CID_26619; DSSTox_RID_81771; DSSTox_GSID_46619; New Straitus; 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-(2-((2-chlorothiophen-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; 1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1H-Imidazole, 1-(2-((2-chloro-3-thienyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-; SMR001550005; (+-)-Tioconazole; CAS-65899-73-2; Vagistat-1 (TN); SR-05000001939; Tioconazole [USAN:BAN:INN:JAN]; Thioconazole; Tioconazole (JAN/USP/INN); 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole; 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-; Tioconazole, 97%; Tioconazole [USAN:USP:INN:BAN:JAN]; UK 20,349; UK-20,349; (.+/-.)-Tioconazole; SCHEMBL41354; 5-23-04-00324 (Beilstein Handbook Reference); MLS003899209; MLS004712040; MLS006010907; CHEMBL1200438; DTXSID3046619; CTK8G3486; HMS2090B12; HMS2093P11; HMS3655K22; HMS3712I10; Pharmakon1600-01505581; EBD39607; HY-B0319; KS-00001F6X; Tox21_112434; BDBM50370218; BG0341; DL-515; GA0099; KM0968; MFCD00057276; NSC759169; s1910; AKOS015906500; Tox21_112434_1; API0004425; CCG-213487; CS-2360; DB01007; KS-5114; NSC-759169; (+-)-1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; NCGC00167430-02; NCGC00167430-03; NCGC00167430-04; AC-13425; AK546825; CC-35071; H949; LS-78340; SBI-0206824.P001; AB0013379; AB2000368; FT-0630756; SW198590-2; C08082; D00890; AB01275523-01; AB01275523_02; AB01275523_03; Tioconazole, VETRANAL(TM), analytical standard; 899T732; A835270; C-21484; Q260326; SR-05000001939-1; SR-05000001939-2; BRD-A33084557-001-01-7; Tioconazole, United States Pharmacopeia (USP) Reference Standard; 1-[2,4-Dichloro-.beta.-[(2-chloro-3-thenyl)-oxy]phenethyl]imidazole; (.+/-.)-1-(2,4-Dichloro-.beta.-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; 1-[(2S)-2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-[2-[(2-chloranylthiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole #; 1-[2-[(2-chloro-3-thiophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-[2-[(2-Chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)-ethyl]imidazole; Vagistat; Tioconazole for system suitability, European Pharmacopoeia (EP) Reference Standard; Tioconazole; 5-23-04-00324 (Beilstein Handbook Reference)
Tiratricol 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodobenzeneacetic acid; 3,3',5-Triiodothyroacetic acid; EINECS 200-086-1
Tobramycin O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-(1->4)]-2-deoxy-D-streptamine; Tobramycin; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Tolazoline 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole; tolazoline; 59-98-3; 2-Benzylimidazoline; Benzidazol; Priscoline; 2-Benzyl-4,5-dihydro-1H-imidazole; Benzazoline; Priscol; 2-Benzyl-2-imidazoline; Olitensol; Vasodilatan; Artonil; Benzolin; Divascol; Imidalin; Kasimid; Lambril; Prefaxil; Vasimid; Vasodil; Phenylmethylimidazoline; Benzylimidazoline; Peripherine; Tolazolin; Dilatol ASI; 2-Benzyl-4,5-imidazoline; Benzolin (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-; Ciba 3259; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole; Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Tolazolina [INN-Spanish]; 2-IMIDAZOLINE, 2-BENZYL-; NSC 35110; Benzolin (vasodilator); Benzolin (vasodilator) (VAN); UNII-CHH9H12AQ3; 2-benzyl imidazoline; EINECS 200-448-9; BRN 0128757; CHH9H12AQ3; Benzalolin; Imidaline; CHEBI:28502; JIVZKJJQOZQXQB-UHFFFAOYSA-N; Tolazolinum; Pridazole; Tolazolina; Tolazoline Monohydrochloride; Tolazoline (INN); CAS-59-97-2; NCGC00016271-01; Tolazine [veterinary] (TN); 2-benzyl-4,5-dihydro-1H-imidazole; hydrochloride; Spectrum_000731; 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; Prestwick0_000060; Prestwick1_000060; Prestwick2_000060; Prestwick3_000060; Spectrum2_001204; Spectrum3_000594; Spectrum4_000357; Spectrum5_001788; ACMC-209mh8; CHEMBL770; 2-Benzylimidazoline, 99%; cid_6048; SCHEMBL34961; BSPBio_000219; BSPBio_002068; KBioGR_000793; KBioSS_001211; 5-23-06-00488 (Beilstein Handbook Reference); DivK1c_000328; SPBio_000988; SPBio_002140; BPBio1_000241; GTPL7310; IMI037; DTXSID3023683; WLN: T5M CN BUTJ B1R; BDBM55436; KBio1_000328; KBio2_001211; KBio2_003779; KBio2_006347; KBio3_001568; NINDS_000328; ZINC125006; HY-A0066; NSC35110; 2-benzyl-2-imidazoline; hydrochloride; ANW-33402; BBL027502; FD7203; MFCD00005182; NSC-35110; SBB003964; STL362893; AKOS000357643; CS-3181; DB00797; MCULE-5694308124; 2-Benzyl-4,5-dihydro-1H-imidazole #; IDI1_000328; NCGC00016271-02; NCGC00016271-03; AS-49302; LS-79571; SC-96012; SBI-0051536.P003; 1H-Imidazole,5-dihydro-2-(phenylmethyl)-; AB0010715; DB-053506; TC-122147; 4CH-003537; B3806; FT-0603251; ST24040015; ST45026160; C07147; D08614; AB00053555-12; AB00053555_14; 059T983; L000960; Q413772; 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)- (9CI); BRD-K46211610-003-05-1; BRD-K46211610-003-15-0; 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; hydrochloride; Tolazoline; 5-23-06-00488 (Beilstein Handbook Reference)
Tolbutamide N-[(Butylamino)carbonyl]-4-methylbenzenesulfonamide; tolbutamide; 64-77-7; Orinase; Artosin; Tolbutamid; Aglicid; Arkozal; Diabetol; Dolipol; Rastinon; Tolumid; Diaben; Orabet; 1-Butyl-3-tosylurea; Tolylsulfonylbutylurea; Willbutamide; Butamide; Diabetamid; Diabuton; Diasulfon; Dirastan; Glyconon; Ipoglicone; Pramidex; Tolbusal; Artozin; Butamid; Drabet; Mobenol; Oralin; Orezan; Orinaz; Oterben; Toluina; Toluvan; 1-Butyl-3-(p-tolylsulfonyl)urea; Sk-tolbutamide; N-n-Butyl-N'-tosylurea; Tolbutamida; Tolbutamidum; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-p-Toluenesulfonyl-3-butylurea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-(Butylcarbamoyl)-4-methylbenzenesulfonamide; Beglucin; Butamidum; Diabesan; N-Butyl-N'-p-toluenesulfonylurea; Tarasina; Tolbutone; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; Arcosal; Tolbet; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; HLS 831; Orinase (TN); N-(Sulfonyl-p-methylbenzene)-N'-N-butylurea; Benzenesulfonamide, N-[(butylamino)carbonyl]-4-methyl-; N-(p-Tolylsulfonyl)-N'-butylcarbamide; Tolbutamidum [INN-Latin]; Tolbutamida [INN-Spanish]; NCI-C01763; N-4-Methylbenzolsulfonyl-N-butylurea; N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide; D 860; Urea, 1-butyl-3-(p-tolylsulfonyl)-; 3-butyl-1-(4-methylbenzenesulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; UNII-982XCM1FOI; CCRIS 592; N-4-(Methylbenzolsulfonyl)-n-butylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; N-(p-Methylbenzenesulfonyl)-N'-butylurea; C12H18N2O3S; HSDB 3393; EINECS 200-594-3; MFCD00027169; NSC 23813; U 2043; CHEMBL782; BRN 1984428; 982XCM1FOI; Benzenesulfonamide, N-((butylamino)carbonyl)-4-methyl-; N-(Sulfonyl-p-methylbenzene)-N'-butylurea; MLS000028399; CHEBI:27999; JLRGJRBPOGGCBT-UHFFFAOYSA-N; N-((Butylamino)carbonyl)-4-methylbenzenesulfonamide; NSC-23813; CAS-64-77-7; NCGC00015999-10; SMR000058363; Tolbutamide form I^L^; DSSTox_CID_1359; 1-BUTYL-3-(4-METHYLBENZENESULFONYL)UREA; DSSTox_RID_76106; DSSTox_GSID_21359; toluran; Oramide; Tolumide; Tolbutamide [INN:BAN:JAN]; NSC-87833; TOLBUTAMIDE USP; SR-01000003059; (butylamino)-N-[(4-methylphenyl)sulfonyl]carboxamide; tolbutamide IL; tolbutamide III; 3-(p-tolylsulfonyl)-1-butylurea; Tolbutamide [USP:INN:BAN:JAN]; Prestwick_471; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(para-tolylsulfonyl) urea; PubChem18102; Spectrum_000447; Tolbutamide form I^H^; Opera_ID_112; 3-butyl-1-[(4-methylbenzene)sulfonyl]urea; Prestwick0_000190; Prestwick1_000190; Prestwick2_000190; Prestwick3_000190; Spectrum2_001210; Spectrum3_000599; Spectrum4_000358; Spectrum5_001272; Lopac-T-0891; N-n-Butyl-N''-tosylurea; WLN: 4MVMSWR D1; T 0891; NCIOpen2_009592; BIDD:PXR0179; CBiol_001920; Lopac0_001154; SCHEMBL15918; BSPBio_000119; BSPBio_001507; BSPBio_002078; KBioGR_000227; KBioGR_000795; KBioGR_002275; KBioSS_000227; KBioSS_000927; KBioSS_002276; 4-11-00-00396 (Beilstein Handbook Reference); MLS001148399; MLS002152944; Toluina|||Tolumid|||Orinase; DivK1c_000341; SPECTRUM1500581; SPBio_001000; SPBio_002040; BPBio1_000131; GTPL6848; Tolbutamide (JP17/USP/INN); Tolbutamide, analytical standard; DTXSID8021359; HMS501B03; KBio1_000341; KBio2_000227; KBio2_000927; KBio2_002275; KBio2_002795; KBio2_003495; KBio2_004843; KBio2_005363; KBio2_006063; KBio2_007411; KBio3_000453; KBio3_000454; KBio3_001578; KBio3_002755; KS-00000XIN; cMAP_000008; NINDS_000341; Bio1_000206; Bio1_000695; Bio1_001184; Bio2_000227; Bio2_000707; HMS1361L09; HMS1568F21; HMS1791L09; HMS1989L09; HMS2089C17; HMS2092M21; HMS2095F21; HMS2232H16; HMS3259A08; HMS3263H09; HMS3402L09; HMS3651N03; HMS3712F21; Pharmakon1600-01500581; BCP09192; HY-B0401; NSC23813; ZINC1530703; 1-n-Butyl-3-(p-tolylsulfonyl)urea; N-Butyl-N''-(p-tolylsulfonyl)urea; Tox21_110279; Tox21_201612; Tox21_302795; Tox21_501154; BDBM50027886; CCG-39141; LS-278; NSC757354; s2443; SBB058188; 1-Butyl-3-(para-tolylsulfonyl)-urea; AKOS015894999; Tox21_110279_1; 1-(p-toluenesulfonyl)-3-n-butyl-urea; CS-2500; DB01124; LP01154; MCULE-9720356859; NC00543; NE30724; NSC-757354; SDCCGSBI-0051121.P004; Tolbutamide 1.0 mg/ml in Acetonitrile; IDI1_000341; IDI1_033977; N-(n-Butyl)-N'-p-toluene-sulfonylurea; NCGC00015999-01; NCGC00015999-02; NCGC00015999-03; NCGC00015999-04; NCGC00015999-05; NCGC00015999-06; NCGC00015999-07; NCGC00015999-08; NCGC00015999-09; NCGC00015999-11; NCGC00015999-12; NCGC00015999-13; NCGC00015999-14; NCGC00015999-15; NCGC00015999-16; NCGC00015999-17; NCGC00015999-19; NCGC00022721-03; NCGC00022721-04; NCGC00022721-05; NCGC00022721-06; NCGC00022721-07; NCGC00022721-08; NCGC00022721-09; NCGC00022721-10; NCGC00256548-01; NCGC00259161-01; NCGC00261839-01; AC-12490; AK115688; AS-14136; CPD000058363; K045; SAM002554936; SC-17768; N-(4-Methylphenylsulfonyl)-N''-butylurea; N-Butyl-N''-(4-methylphenylsulfonyl)urea; SBI-0051121.P003; Tolbutamide 100 microg/mL in Acetonitrile; AB1004876; DB-054728; AB00052110; EU-0101154; FT-0603265; ST24031344; ST50409552; SW196681-3; BIM-0051121.0001; C07148; D00380; J10018; U-2043; AB00052110-16; AB00052110_17; AB00052110_18; Tolbutamide, VETRANAL(TM), analytical standard; Q414275; N-((butylamino) carbonyl)-4-methylbenzenesulfonamide; SR-01000003059-2; SR-01000003059-4; SR-01000003059-7; W-104820; BRD-K85119730-001-06-5; BRD-K85119730-001-17-2; Z44591715; Tolbutamide, European Pharmacopoeia (EP) Reference Standard; 1-(([(Butylamino)carbonyl]amino)sulfonyl)-4-methylbenzene #; Tolbutamide, United States Pharmacopeia (USP) Reference Standard; Tolbutamide; D 860
Tolfenamic acid 2-[(3-Chloro-2-methylphenyl)amino]benzoic acid; Tolfenamic acid; Acide tolfenamique [INN-French]
Trehalose alpha-D-Glucopyranoside, alpha-D-Glucopyranosyl; Trehalose; EINECS 202-739-6
Trenbolone (17beta)-17-Hydroxyestra-4,9,11-trien-3-one; Trenbolone; 10161-33-8; 17beta-Trenbolone; Trienbolone; 17-beta-Trenbolone; Trenbolonum [INN-Latin]; Trembolona [INN-Spanish]; 17-beta-Hydroxyestra-4,9,11-trien-3-one; UNII-P53R4420TR; RU 2341; CCRIS 1654; BRN 5756203; CHEBI:35018; P53R4420TR; Estra-4,9,11-trien-3-one, 17-hydroxy-, (17b)-; DSSTox_CID_14192; DSSTox_RID_79122; (17beta)-17-hydroxyestra-4,9,11-trien-3-one; DSSTox_GSID_34192; (+)-Trenbolone; ESTRA-4,9,11-TRIEN-3-ONE, 17-beta-HYDROXY-; TremboloTrenbolonum; Finajet; beta-Trenbolone; (8S,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,14,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-3-one; CAS-10161-33-8; Trenbolone [INN:BAN]; Trenbolone (INN); 17beta-Hydroxyestra-4,9,11-trien-3-one; SCHEMBL141915; (+)-Trenbolone; |A-Trenbolone; EST003; CHEMBL3182355; DTXSID0034192; CTK4A0013; BCP12545; ZINC3814429; Tox21_200539; Tox21_303654; 4130AH; MFCD00214395; AKOS015894852; Trenbolone 1.0 mg/ml in Acetonitrile; CS-1417; DB11551; 3-oxo-estra-4,9,11-triene-17b-ol; NCGC00248686-01; NCGC00257511-01; NCGC00258093-01; CC-35247; HY-17433; LS-64821; 17-b-Hydroxyestra-4,9,11-trien-3-one; 17beta-Hydroxyestr-4,9,11-trien-3-one; C14261; D08627; W-5091; 161T338; C-17014; Q904833; Trenbolone, analytical standard, for drug analysis; Estra-4,9,11-trien-3-one, 17-hydroxy-, (17|A)-; Estra-4,9,11-trien-3-one, 17-hydroxy-, (17beta)-; Estra-4,9,11-trien-3-one, 17-hydroxy-, (17-beta)-; Estra-4,9,11-trien-3-one, 17-hydroxy-, (17-beta)- (9CI); Trenbolone; BRN 5756203
Treosulphan (2S,3S)-1,2,3,4-Butanetetrol, 1,4-Dimethanesulfonate; Treosulfan; CB 2562
Tretinoin Retinoic acid; 4-09-00-02387 (Beilstein Handbook Reference)
Triamterene 2,4,7-TRIAMINO-6-PHENYL PTERIDINE; Triamterene; 5-26-17-00447 (Beilstein Handbook Reference)
Tributyrin 1,2,3-Propanetriyl ester butanoic acid; Tributyrin; 4-02-00-00799 (Beilstein Handbook Reference)
Tricaprylin Octanoic acid 1,2,3-propanetriyl ester; Caprylic acid, 1,2,3-propanetriyl ester; 4-02-00-00991 (Beilstein Handbook Reference)
Trichlormethiazide 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; Trichlormethiazide; Achletin
Triclosan 5-Chloro-2-(2,4-dichlorophenoxy)phenol; triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Stri-Dex Face Wash; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No. 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA Pesticide Chemical Code 054901; BRN 2057142; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; XEFQLINVKFYRCS-UHFFFAOYSA-N; 4NM5039Y5X; MFCD00800992; TCL; NCGC00159417-02; NCGC00159417-05; NCGC00159417-06; AK-73001; Aquasept; Sapoderm; DSSTox_CID_12498; DSSTox_RID_78958; DSSTox_GSID_32498; Q-201866; Irgasan DP 300; Cloxifenol; 2-(2,4-dichlorophenoxy)-5-chlorophenol; SMR000471847; Triclosan [USAN:BAN:INN]; CAS-3380-34-5; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; Triclosan (USP/INN); SR-01000762974; Trichlorosan; Sterzac; Stri-Dex cleansing bar (TN); CCRIS 9253; Triclosan USP; 1nhg; Triclosan [USAN:USP:INN:BAN]; Triclosan; Irgasan; Irgasan (Triclosan); Irgasan DP 30; TCCP; PubChem9026; CH-3565; Neostrata Antibacterial Facial Cleanser; 3p9t; 4w9n; Epitope ID:119683; SCHEMBL3269; 88032-08-0; KSC498G0D; MLS001066347; MLS001074876; MLS001335937; MLS001335938; BDBM8726; ZINC2216; DTXSID5032498; CTK3J8301; BII1002; ZX-AFC000465; HMS2093L17; HMS2270M06; HMS3259K19; HMS3715H11; Pharmakon1600-01505465; Irgasan, >=97.0% (HPLC); DNDI1246774; HY-B1119; KS-000009AG; Tox21_111648; Tox21_400079; ANW-42338; DP 300; GA5716; NSC759151; s4541; SBB058565; STL451034; Triclosan 100 microg/mL in Methanol; AKOS015850380; Tox21_111648_1; API0004498; CCG-213459; CH-3635; CS-4718; DB08604; KS-5356; MCULE-2614621397; NC00516; NSC-759151; RTR-014090; TRA0068104; Triclosan 10 microg/mL in Cyclohexane; NCGC00159417-03; NCGC00159417-04; NCGC00159417-07; NCGC00159417-08; 2,4,4'-trichloro-2'-hydroxydiphenylethe; AC-10667; BR-73001; CPD000471847; LS-67854; SAM002554907; SC-16588; 5-chloro-2-(2, 4-dichlorophenoxy)phenol; SBI-0206807.P001; AX8020299; ST2411924; TR-014090; 5-chloro-2-(2,4-di-chloro-phenoxy)-phenol; FT-0609773; ST50826110; C12059; D06226; J10025; M-6446; S00100; 5-Chloro-2-(2,4-dichlorophenoxy)phenol, 97%; AB00698074_08; Triclosan, Antibiotic for Culture Media Use Only; 380T345; A821950; C-18186; Q408646; 2-[2,4-bis(chloranyl)phenoxy]-5-chloranyl-phenol; SR-01000762974-2; SR-01000762974-3; BRD-K41731458-001-04-5; BRD-K41731458-001-09-4; Triclosan, certified reference material, TraceCERT(R); F2173-0825; Triclosan, United States Pharmacopeia (USP) Reference Standard; Triclosan, Pharmaceutical Secondary Standard; Certified Reference Material; BRN 2057142
Tridecanoic acid 4-02-00-01117 (Beilstein Handbook Reference)
Triethyl phosphate 4-01-00-01339 (Beilstein Handbook Reference)
Triethylenetetramine N1,N2-bis(2-Aminoethyl)-1,2-ethanediamine; Triethylenetetramine; 4-04-00-01242 (Beilstein Handbook Reference)
Trifluoperazine 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; trifluoperazine; Trifluperazine; Trifluoroperazine; Trifluoperazin; Triflurin; Triperazine; 117-89-5; Trifluoperazina; Trifluoromethylperazine; Flurazine; Stelazine; Trifluoperazinum; Trifluroperizine; Trifluoperazine hydrochloride; Trifluoperazina [Italian]; RP 7623; Fluoperazine; Triphthasine; Trifluoperazine [INN:BAN]; TFP; Trifluoperazinum [INN-Latin]; Trifluoperazina [INN-Spanish]; Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; NSC 17474; Calmazine; UNII-214IZI85K3; CCRIS 6994; C21H24F3N3S; HSDB 3195; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methylpiperazin-1-yl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; EINECS 204-219-4; NSC 46061; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; SKF 5019; CHEBI:45951; 214IZI85K3; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Tripfluoperazine Hydrochloride; 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-; NSC17474; 10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-; MLS001146870; MLS002702821; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; SMR001566649; NSC-17474; Trifluoperazine (INN); 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; CAS-440-17-5; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); 2-Trifluoromethyl-10-[3'-(1-methyl-4-piperazinyl)propyl]phenothiazine; Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-; Trifluoperazin HCl; NCI17474; Synklor (Salt/Mix); Stelazine (Salt/Mix); Triftazin (Salt/Mix); Spectrum_000668; Terfluzine (Salt/Mix); Triftazine (Salt/Mix); Jatroneural (Salt/Mix); Fluoperazine (Salt/Mix); Triphthazine (Salt/Mix); 605-75-4; Prestwick0_000313; Prestwick1_000313; Prestwick2_000313; Prestwick3_000313; Spectrum2_000828; Spectrum3_001374; Spectrum4_000368; Spectrum5_001553; Lopac-T-8516; Biomol-NT_000060; CHEMBL422; cid_5566; NCIStruc1_001127; NCIStruc2_001093; BIDD:PXR0132; Lopac0_001232; SCHEMBL24866; BSPBio_000306; BSPBio_001190; BSPBio_002928; GTPL214; KBioGR_000530; KBioGR_000835; KBioGR_002431; KBioSS_000530; KBioSS_001148; KBioSS_002437; MLS006011857; DivK1c_000843; SPBio_000755; SPBio_002525; BPBio1_000338; BPBio1_001345; DTXSID1046928; BDBM79181; cid_2913535; KBio1_000843; KBio2_000530; KBio2_001148; KBio2_002431; KBio2_003098; KBio2_003716; KBio2_004999; KBio2_005666; KBio2_006284; KBio2_007567; KBio3_000959; KBio3_000960; KBio3_002148; KBio3_002910; cMAP_000048; NINDS_000843; ZEWQUBUPAILYHI-UHFFFAOYSA-N; Bio1_000458; Bio1_000947; Bio1_001436; Bio2_000435; Bio2_000915; HMS1362L11; HMS1792L11; HMS1990L11; HMS2089J11; HMS3429O07; KUC109776N; EX-A3330; CCG-37306; NCGC00013226; PDSP1_001300; PDSP2_001284; s5856; STK182873; ZINC19418959; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; AKOS001487920; DB00831; MCULE-3726407978; SDCCGSBI-0051199.P005; IDI1_000843; IDI1_002190; KSC-210-031; MRF-0000088; QTL1_000085; NCGC00013226-02; NCGC00013226-03; NCGC00013226-04; NCGC00013226-05; NCGC00013226-06; NCGC00013226-07; NCGC00013226-08; NCGC00013226-09; NCGC00013226-10; NCGC00013226-11; NCGC00013226-12; NCGC00013226-13; NCGC00013226-15; NCGC00024251-03; NCGC00024251-04; NCGC00024251-05; NCGC00024251-06; NCGC00024251-07; M989; NCI60_001427; NCI60_004087; SC-95890; SBI-0051199.P003; AX8155275; LS-105595; AB00053558; FT-0650159; 5858-EP2302003A1; 5858-EP2309505A1; C07168; D08636; AB00053558-27; AB00053558_28; AB00053558_29; L001075; Q1752915; SR-01000003020-6; BRD-K89732114-001-02-6; BRD-K89732114-001-03-4; BRD-K89732114-001-05-9; BRD-K89732114-300-05-5; BRD-K89732114-300-07-1; 10-(.gamma.-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiozine; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine #; 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)phenothiazine; hydrochloride; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; hydrochloride; 10-[3-(4-methylpiperazino)propyl]-2-(trifluoromethyl)phenothiazine; hydrochloride; Trifluoperazine; CCRIS 6994
Trifluoroethanol 2,2,2-Trifluoroethanol; 2,2,2-TRIFLUOROETHANOL; 75-89-8; Trifluoroethanol; Ethanol, 2,2,2-trifluoro-; trifluoro ethanol; Trifluoroethyl alcohol; 2,2,2-Trifluoroethan-1-Ol; 2,2,2-Trifluoroethyl alcohol; Fluorinol 85; TFE; Perfluoro-1,1-dihydroethanol; tfetoh; CF3CH2OH; NSC 451; 2,2,2-trifluoro-ethanol; beta,beta,beta-Trifluoroethyl alcohol; UNII-8T8I76KYF1; TFEA; 2,2,2-TRIFLUORETHANOL; 1h,1h-trifluoroethanol; EINECS 200-913-6; MFCD00004672; BRN 1733203; ethanol, 2,2,2-trifluoro; AI3-25486; 8T8I76KYF1; CHEBI:42330; RHQDFWAXVIIEBN-UHFFFAOYSA-N; BETA,BETA,BETA-TRIFLUOROETHANOL; .beta.,.beta.,.beta.-Trifluoroethyl alcohol; ETF; 2,2,2-Trifluoroethanol, 99.8%, extra pure; trifluorethanol; trifluroethanol; 2,2-Trifluoroethanol; 2,2,-trifluoroethanol; 2,2,2trifluoroethanol; PubChem12849; 2,2,2-trifluoroetanol; 2,2,2-trifluroethanol; 2 2 2-trifluoroethanol; 2,2,2 trifluoroethanol; 2.2,2-trifluoroethanol; 2.2.2-trifluoroethanol; 2,2,2-trifluoroethanole; WLN: Q1XFFF; 2,2,2-trifloro ethanol; DSSTox_CID_1751; 2,2,2 trifluoro-ethanol; 2,2,2,-trifluoroethanol; 2,2,2-tri-fluoroethanol; 2,2,2-trifluoro ethanol; Trifluoroethanol (Related); ACMC-209p0p; EC 200-913-6; 2,2-Trifluoroethyl alcohol; SCHEMBL4869; 2,2,2-trifluoro -ethanol; DSSTox_RID_76304; 2,2,2-trifluoroethylalcohol; DSSTox_GSID_21751; 4-01-00-01370 (Beilstein Handbook Reference); KSC377K2F; 1,1,1-Trifluoro-2-ethanol; CHEMBL116675; Fluorotelomer (linear) alcohols; NSC451; DTXSID0021751; Trifluoroethyl alcohol (Related); CTK2H7522; beta, beta, beta-trifluoroethanol; DTXSID10893581; DTXSID90893802; NSC-451; NOCAS_893581; NOCAS_893802; ETHANOL,2,2,2-TRIFLUORO; ACT10236; BCP31089; KS-00000UR2; ZINC3860799; Tox21_200905; ANW-36695; BBL008539; Fluorotelomer (linear) n:2 alcohols; RW2094; STK260853; .beta.,.beta.-Trifluoroethyl alcohol; AKOS000119834; AS02919; DB03226; MCULE-5503592317; RTR-031638; CAS-75-89-8; NCGC00248871-01; NCGC00258459-01; 2,2,2-TRIFLUORO ETHYL AMINE HCL; BP-21406; LS-67082; SC-25841; VS-01941; AB0007403; AB1010861; TR-031638; AM20100728; FT-0609034; ST50705577; X-4007; 32487-EP2274983A1; 32487-EP2289868A1; 32487-EP2289892A1; 32487-EP2295437A1; 32487-EP2298775A1; 32487-EP2301918A1; 32487-EP2301933A1; 32487-EP2308492A1; 32487-EP2308857A1; 32487-EP2308864A1; 32487-EP2311827A1; 2,2,2-Trifluoroethanol, ReagentPlus(R), >=99%; 2,2,2-Trifluoroethanol redistilled from glass grade; InChI=1/C2H3F3O/c3-2(4,5)1-6/h6H,1H; J-506750; Q2474643; F0001-1907; 2,2,2-Trifluoroethanol, analytical standard, for NMR spectroscopy; Trifluoroethanol; Ethanol, 2,2,2-trifluoro-; Trifluoroethyl alcohol; 2,2,2-Trifluoroethanol, BioUltra, for molecular biology, >=99.0% (GC); Trifluoroethanol; 4-01-00-01370 (Beilstein Handbook Reference)
Triglyme 2,5,8,11-Tetraoxadodecane; Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; TEGDIME; TEGDME; Dimethyl ether of triethylene glycol; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-METHOXY-2-[2-(2-METHOXY-ETHOXY]-ETHANE; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; 32YXG88KK0; triethyleneglycol dimethyl ether; DTXSID8026224; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene glycol dimethyl ether, 99%, stabilized; Glyme-4; DSSTox_CID_6224; 2,8,11-Tetraoxadodecane; EC 203-977-3; ACMC-1C6S6; DSSTox_RID_78066; DSSTox_GSID_26224; SCHEMBL16126; KSC178A6F; 1,2-Bis(methoxyethoxy)ethane; triethylene glycol dimethylether; CHEMBL1235255; CTK0H8062; Ethane,2-bis(2-methoxyethoxy)-; (CH3O(CH2)2OCH2)2; NSC66400; ZINC1693863; Tox21_300509; 2186AA; ANW-16480; LS-553; MFCD00008504; NSC-66400; SBB060897; AKOS009158244; DB02078; MCULE-9670046114; RTR-033142; TRA0080110; KS-0000006K; NCGC00164017-01; NCGC00164017-02; NCGC00254323-01; CAS-112-49-2; CC-35336; 1,2-Bis(2-methoxyethoxy) Ethane, Reagent; DB-060211; TR-033142; B0496; FT-0659858; FT-0755020; ST24027330; ST50825121; 23265-EP2289897A1; 23265-EP2314584A1; 23265-EP2371797A1; 23265-EP2371798A1; 23265-EP2371800A1; 23265-EP2371804A1; C-34604; Q2453066; Triethylene glycol dimethyl ether, ReagentPlus(R), 99%; Z1245664652; Triethylene glycol dimethyl ether, analytical reference material; Triethylene glycol dimethyl ether, Vetec(TM) reagent grade, 98%; 2,5,8,11-tetraoxadodecane; 1,2-bis(2-methoxyethoxy)ethane; triethylene glycol dimethyl ether; 1,2bis(2methoxyethoxy)ethane; triethylene glycoldimethylether (tegdme); 2,5,8,11-tetraoxadodecane 1,2-bis(2-methoxyethoxy)ethane triethylene glycol dimethyl ether 1,2bis(2methoxyethoxy)ethane triethylene glycoldimethylether (tegdme); Triglyme; 4-01-00-02401 (Beilstein Handbook Reference)
Trihexyphenidyl alpha-Cyclohexyl-alpha-phenyl-1-piperidinepropanol; Trihexyphenidyl; 5-20-02-00231 (Beilstein Handbook Reference)
Trilostane (4alpha,5alpha,17beta)-4,5-Epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile; Trilostane; Androstane-2-carbonitrile, 4,5-epoxy-17-hydroxy-3-oxo-, (2-alpha,4-alpha,5-alpha,17-beta)-
Trimeprazine N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; trimeprazine; Alimemazine; Methylpromazine; Alimezine; Repetin; Teralen; 84-96-8; dl-Trimeprazine; Trimeperazine; Bayer 1219; Temaril; (+-)-Alimemazine; (+-)-Trimeprazine; Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Alimemazina [INN-Spanish]; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; HSDB 3197; EINECS 201-577-3; CHEMBL829; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; 10H-Phenothiazine-10-propanamine, N,N,beta-trimethyl-; CHEBI:9725; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; Phenothiazine, 10-(3-(dimethylamino)-2-methylpropyl)-; 10H-Phenothiazine-10-propanamine, N,N,.beta.-trimethyl-; Alimemazina; Alimemazinum; Isobutrazine; 10-[3-(Dimethylamino)-2-methylpropyl]phenothiazine; dimethyl[2-methyl-3-(10H-phenothiazin-10-yl)propyl]amine; Teralene; Repeltin (TN); Alimemazine (INN); Trimeprazine (BAN); NSC17476; Phenothiazine, 10-[3-(dimethylamino)-2-methylpropyl]-; Temaril (Salt/Mix); Vanectyl (Salt/Mix); Nedeltran (Salt/Mix); Theralene (Salt/Mix); Vallergan (Salt/Mix); (.+/-.)-Alimemazine; (.+/-.)-Trimeprazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine; SCHEMBL18993; GTPL7237; N,N,2-trimethyl-3-phenothiazin-10-yl-propan-1-amine; DTXSID9023708; ZZHLYYDVIOPZBE-UHFFFAOYSA-N; BDBM50062261; AKOS015963415; API0009048; DB01246; QTL1_000086; AC-19920; HY-12752; SBI-0051545.P002; LS-105476; AB00053560; CS-0012341; C07172; D07125; AB00053560_08; 084T968; L000989; 10-[2-Methyl-3-(dimethylamino)propyl]phenothiazine; Q2623251; BRD-A49225603-045-05-0; Dimethyl-(2-methyl-3-phenothiazin-10-yl-propyl)-amine; N,N,2-Trimethyl-3-(10H-phenothiazin-10-yl)-1-propanamine #; Trimeprazine; Alimemazina [INN-Spanish]
Trimesic acid 1,3,5-Benzenetricarboxylic acid; Trimesic acid; AI3-06468
Trimethadione 3,5,5-Trimethyl-2,4-oxazolidinedione; trimethadione; 127-48-0; Troxidone; Tridione; Trimetadione; Trimethadion; Trimetin; Absentol; Convenixa; Convexina; Epidione; Petidion; Petimalin; Tioxanona; Tridilona; Trimedal; Trimethin; Trioxanona; Absetil; Epixal; Petidon; Petilep; Ptimal; Tridion; Edion; Minoaleviatin; Trimethdione; Minoaleuiatin; Tredione; Tricione; Trilidona; Trimedone; Trimethinum; Trioksal; Triozanona; Tromedone; Epidone; Etydion; Pitmal; Tridone; 3,5,5-Trimethyloxazolidine-2,4-dione; Trimetadione [DCIT]; 3,5,5-Trimethyl-2,4-oxazolidinedione; Mino-Aleviatin; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 2,4-OXAZOLIDINEDIONE, 3,5,5-TRIMETHYL-; Trimetadiona [INN-Spanish]; Trimethadionum [INN-Latin]; A 2297; 3,3,5-Trimethyl-2,4-diketooxazolidine; UNII-R7GV3H6FQ4; NSC 15799; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5,-Trimethyloxazolidine-2,4-dione; EINECS 204-845-8; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]; BRN 0121627; R7GV3H6FQ4; C6H9NO3; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; trimethyl-1,3-oxazolidine-2,4-dione; NCGC00016383-01; Trimetadiona; Trimethadionum; CAS-127-48-0; DSSTox_CID_1396; 2, 3,5,5-trimethyl-; DSSTox_RID_76137; DSSTox_GSID_21396; 3,5-Trimethyl-2,4-oxazolidinedione; 3,5-Trimethyl-2,4-diketooxazolidine; WLN: T5OVNV EHJ C1 E1 E1; Trimethadione [INN:JAN]; Tridione (TN); Mino aleviatin; Tridione Dulcet; Trimethadione [USP:INN:BAN:JAN]; Prestwick_815; 3,5,5-trimethyl-2,4-dioxooxazolidine; ACMC-1BYOW; Prestwick0_000515; Prestwick1_000515; Prestwick2_000515; Prestwick3_000515; CHEMBL695; Trimethadione (JP17/INN); SCHEMBL28882; BSPBio_000469; MLS001076685; SPBio_002390; BPBio1_000517; CHEBI:9727; GTPL7316; DTXSID9021396; CTK7H6925; IRYJRGCIQBGHIV-UHFFFAOYSA-; IRYJRGCIQBGHIV-UHFFFAOYSA-N; HMS1569H11; HMS2093D10; HMS2096H11; HMS2235E12; HMS3713H11; Pharmakon1600-01505466; HY-A0092; KS-00001F5Z; NSC15799; ZINC1530710; Tox21_110408; Tox21_200231; BDBM50227239; FCH917493; NSC-15799; NSC169503; NSC759152; s5567; Trimethadione 1.0 mg/ml in Methanol; AKOS006229172; CCG-213460; DB00347; LS-7736; MCULE-4761457520; NSC-169503; NSC-759152; 3,5,5-Trimethyl oxazolidine-2,4-dione; NCGC00016383-02; NCGC00016383-03; NCGC00016383-05; NCGC00257785-01; SMR000499583; SBI-0206923.P001; TC-169983; FT-0694585; ST50411784; D00392; 20503-EP2275420A1; 20503-EP2280008A2; 20503-EP2298764A1; 20503-EP2298765A1; 20503-EP2308867A2; 20503-EP2308870A2; 20503-EP2314585A1; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione #; C-52877; Q827916; SR-01000763540; J-005496; SR-01000763540-2; BRD-K16606819-001-07-7; 3,5,5,-Trimethyloxazolidine-2,4-dione, analytical standard; Trimethadione, European Pharmacopoeia (EP) Reference Standard; InChI=1/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3; Trimethadione, United States Pharmacopeia (USP) Reference Standard; Trimethadione; A 2297